The objective of this Assessment is to evaluate the clinical effectiveness of magnetic resonance imaging (MRI) of the breast for management of patients with locally advanced breast cancer who are being referred for neoadjuvant chemotherapy in order to shrink the tumor to a size eligible for breast conservation therapy (BCT). Assessment of the extent of residual tumor after neoadjuvant therapy by conventional techniques (physical exam and mammography) is relatively inaccurate. Breast MRI has been proposed to evaluate the extent of tumor after completion of neoadjuvant chemotherapy to determine which patients have become eligible for BCT. The MRI scan before chemotherapy is used for comparison to demonstrate tumor location so that the tumor can be optimally evaluated after chemotherapy even when the tumor size and degree of contrast enhancement are greatly reduced in a very responsive tumor.